Anti-CHD3 antibody [EPNCIR110A],Abcam,AB109195
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . Collaborations This antibody was developed as part of a collaboration between Epitomics, the National Cancer Institute's Center for Cancer Research and the lab of Gordon Hager. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Rat, Human
Application
WB, ICC/IF, Flow Cyt (Intra), IHC-P
Platform ID
BAB511043990
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data ATP-dependent helicase that binds and distorts nucleosomal DNA (PubMed : 28977666). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed : 16428440, PubMed : 28977666, PubMed : 30397230, PubMed : 9804427). Involved in transcriptional repression as part of the NuRD complex (PubMed : 27068747). Required for anchoring centrosomal pericentrin in both interphase and mitosis, for spindle organization and centrosome integrity (PubMed : 17626165). See full target information CHD3
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.